Patents by Inventor Eliel Bayever

Eliel Bayever has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods For Treating Pancreatic Cancer Using Combination Therapies
    Publication number: 20230088999
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Application
    Filed: May 25, 2022
    Publication date: March 23, 2023
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
    Publication number: 20230062425
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Application
    Filed: April 1, 2022
    Publication date: March 2, 2023
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • Methods for treating pancreatic cancer using combination therapies
    Patent number: 11369597
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: June 28, 2022
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
    Patent number: 11344552
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: May 31, 2022
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
    Publication number: 20220096458
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Application
    Filed: March 17, 2021
    Publication date: March 31, 2022
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
    Patent number: 10980795
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: April 20, 2021
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • Treatment of Breast Cancer with Liposomal Irinotecan
    Publication number: 20200360367
    Abstract: Provided are methods for treating breast cancer in a patient by administering effective amounts of liposomal irinotecan sucrosofate (MM-398). The breast cancer may be triple negative breast cancer (TNBC), estrogen receptor/progesterone receptor (ER/PR) positive breast cancer, ER-positive breast cancer, or PR-positive breast cancer, or metastatic breast cancer.
    Type: Application
    Filed: December 11, 2019
    Publication date: November 19, 2020
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Eliel Bayever, Jonathan Basil Fitzgerald, Jaeyeon Kim, Stephan Klinz
  • Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
    Patent number: 10744130
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: August 18, 2020
    Assignee: Ipsen Biopharm Ltd.
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • Treatment of Breast Cancer with Liposomal Irinotecan
    Publication number: 20190142822
    Abstract: Provided are methods for treating breast cancer in a patient by administering effective amounts of liposomal irinotecan sucrosofate (MM-398). The breast cancer may be triple negative breast cancer (TNBC), estrogen receptor/progesterone receptor (ER/PR) positive breast cancer, ER-positive breast cancer, or PR-positive breast cancer, or metastatic breast cancer.
    Type: Application
    Filed: July 16, 2018
    Publication date: May 16, 2019
    Inventors: Eliel Bayever, Jonathan Basil Fitzgerald, Jaeyeon Kim, Stephan Klinz
  • Methods For Treating Pancreatic Cancer Using Combination Therapies
    Publication number: 20190117644
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Application
    Filed: June 19, 2018
    Publication date: April 25, 2019
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
    Publication number: 20190117643
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Application
    Filed: June 19, 2018
    Publication date: April 25, 2019
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
    Publication number: 20180078556
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Application
    Filed: November 10, 2017
    Publication date: March 22, 2018
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • Methods for Treating Pancreatic Cancer Using Combination Therapies
    Publication number: 20180008591
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Application
    Filed: July 31, 2017
    Publication date: January 11, 2018
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • METHODS FOR TREATING PANCREATIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN
    Publication number: 20170368056
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Application
    Filed: July 18, 2017
    Publication date: December 28, 2017
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • Methods for treating pancreatic cancer using combination therapies
    Patent number: 9717724
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: August 1, 2017
    Assignee: Ipsen Biopharm Ltd.
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • TREATMENT OF PANCREATIC CANCER WITH LIPOSOMAL IRINOTECAN
    Publication number: 20170202840
    Abstract: A liposome-encapsulated formulation of irinotecan can be used for the treatment of pancreatic cancer in combination with 5-fluorouracil and leucovorin, including treatment of patients diagnosed with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine.
    Type: Application
    Filed: January 11, 2017
    Publication date: July 20, 2017
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • Treatment of Breast Cancer with Liposomal Irinotecan
    Publication number: 20170151226
    Abstract: Provided are methods for treating breast cancer in a patient by administering effective amounts of liposomal irinotecan sucrosofate (MM-398). The breast cancer may be triple negative breast cancer (TNBC), estrogen receptor/progesterone receptor (ER/PR) positive breast cancer, ER-positive breast cancer, or PR-positive breast cancer, or metastatic breast cancer.
    Type: Application
    Filed: December 9, 2016
    Publication date: June 1, 2017
    Inventors: Eliel Bayever, Jonathan Basil Fitzgerald, Jaeyeon Kim, Stephan Klinz
  • METHODS FOR TREATING PANCREATIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN
    Publication number: 20170065578
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Application
    Filed: November 2, 2016
    Publication date: March 9, 2017
    Inventors: Eliel Bayever, NAVREET DHINDSA, JONATHAN BASIL FITZGERALD, PETER LAIVINS, VICTOR MOYO, CLET NIYIKIZA, JAEYEON KIM
  • Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
    Publication number: 20170049775
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Application
    Filed: August 19, 2016
    Publication date: February 23, 2017
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • METHODS FOR TREATING PANCREATIC CANCER USING COMBINATION THERAPIES
    Publication number: 20170049768
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Application
    Filed: November 2, 2016
    Publication date: February 23, 2017
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim, Bambang Adiwijaya